Simon Barnett
Intellia and Ultragenyx’s Clinical Updates, Novo Holdings’ Catalent Acquisition, and NanoString Bankruptcy
Best podcasts with Simon Barnett
Ranked by the Snipd community
Feb 9, 2024 • 45min
Intellia and Ultragenyx’s Clinical Updates, Novo Holdings’ Catalent Acquisition, and NanoString Bankruptcy; Simon Barnett
Gene therapy updates for rare diseases by Intellia and Ultragenyx, Novo Holdings' acquisition of Catalent for $16.5B to keep up with drug demand, NanoString bankruptcy after patent infringement lawsuit, and an interview with Simon Barnett on advancing biotech's digitization and the intersection of machine learning and biophysics in structural biology.
